Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia
Open Access
- 15 July 2011
- Vol. 118 (3), 828-838
- https://doi.org/10.1002/cncr.26337
Abstract
BACKGROUND: Treatment regimens for childhood acute lymphoblastic leukemia (ALL) contain neurotoxic agents that may interfere with neuromuscular health. In this study, the authors examined associations between neuromuscular impairments and physical function and between neuromuscular impairments and doses of vincristine and intrathecal methotrexate used to treat leukemia among survivors of childhood ALL. METHODS: ALL survivors >10 years from diagnosis participated in neuromuscular performance testing. Treatment data were abstracted from medical records. Regression models were used to evaluate associations between treatment factors, neuromuscular impairments, and physical performance. RESULTS: Among 415 survivors (median age, 35 years; age range, 21‐52 years), balance, mobility, and 6‐minute walk (6MW) distances were 1.3 standard deviations below age‐specific and sex‐specific values in 15.4%, 3.6%, and 46.5% of participants, respectively. Impairments included absent Achilles tendon reflexes (39.5%), active dorsiflexion range of motion (ROM) 2 were 3.4 times more likely (95% confidence interval, 1.2‐9.8 times more likely) to have impaired ROM than survivors who received no intrathecal methotrexate, and survivors who received cumulative vincristine doses ≥39 mg/m2 were 1.5 times more likely (95% CI, 1.0‐2.5 times more likely) to have impaired ROM than survivors who received lower cumulative doses of vincristine. Higher intrathecal methotrexate doses were associated with reduced knee extension strength and 6MW distances. CONCLUSIONS: Neuromuscular impairments were prevalent in childhood ALL survivors and interfered with physical performance. Higher cumulative doses of vincristine and/or intrathecal methotrexate were associated with long‐term neuromuscular impairments, which have implications on future function as these survivors age. Cancer 2012;. © 2011 American Cancer Society.Keywords
This publication has 41 references indexed in Scilit:
- Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac healthExpert Review of Hematology, 2011
- Prospective medical assessment of adults surviving childhood cancer: Study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort StudyPediatric Blood & Cancer, 2010
- Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985–2001Leukemia, 2009
- Comparison of Neurocognitive Functioning in Children Previously Randomly Assigned to Intrathecal Methotrexate Compared With Triple Intrathecal Therapy for the Treatment of Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2009
- Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemiaJournal of the Peripheral Nervous System, 2009
- A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemiaBlood, 2009
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationThe New England Journal of Medicine, 2009
- Bone mineral density in young adult survivors of acute lymphoblastic leukemiaCancer, 2008
- Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristineCancer, 2006
- Foot and leg problems are important determinants of functional status in community dwelling older peopleDisability and Rehabilitation, 2005